MIST — Milestone Pharmaceuticals Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1408443 ·
Last close
$0.41
Market Cap
$51.44M
52W High
$3.06
52W Low
$0.36
ADV30
1,692,724
Next earnings
2026-11-13
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 2,963,000 2,638,000 -25,052,000 -25,796,000 162,695,000 144,472,000 168,912,000
Jun 2026 559,000 527,000 -25,630,000 -28,614,000 181,625,000 169,728,000 163,407,000
Mar 2026 238,000 224,000 -23,663,000 -26,066,000 193,734,000 71,317,000 157,685,000
Dec 2025 1,546,000 — -17,257,000 -17,409,000 113,561,000 73,046,000 71,792,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-61,290,000
Investing CF
$-319,000
Financing CF
$188,838,000
CapEx
$-356,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.73
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-485,283,000
Inventory
$4,722,000
Receivables
$3,961,000
ST Investments
$881,000
EBIT TTM
$-73,199,000
Pretax Income TTM
$-84,011,000
Interest Exp TTM
$10,812,000
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,343,000
EBITDA
$-78,207,000
Free Cash Flow
$-41,687,376
Enterprise Value
$44,496,672
Total Cash
$170,608,992
Total Debt
$141,832,000
Shares Out
124,497,980
Trailing EPS
$-0.68
Book Value
$0.13
ROE
-35522.6%
ROA
-42.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,546,000 -62,140,000 -63,058,000 113,561,000 71,792,000 41,769,000 -49,041,000
Dec 2024 0 -42,102,000 -41,519,000 75,499,000 62,352,000 13,147,000 -28,848,000
Dec 2023 1,000,000 -61,098,000 -59,685,000 75,226,000 58,455,000 16,771,000 -46,424,000
Dec 2022 5,000,000 -59,642,000 -58,388,000 74,483,000 8,135,000 66,348,000 -52,469,000

TTM Snapshot

Revenues TTM
$2,504,000
NetIncome TTM
$-84,011,000
OpCashFlow TTM
—
Assets (Latest)
$181,625,000
Forward EPS
$-0.75

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $0.50 · spot: $0.46 · call volume: 622 · put volume: 1
Expected Move to 2026-12-18: ±$0.12 (26.06%) — implied range $0.34 – $0.58 · ATM straddle on $0.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
HOWL Werewolf Therapeutics, Inc. $51.03M $1.05 —
AZR Azora Therapeutics, Inc. (DE) $52.36M $3.66 —
SPRO Spero Therapeutics, Inc. $52.51M $0.90 —
GANX Gain Therapeutics, Inc. $52.54M $1.18 —
IBIO iBio, Inc. $52.71M $0.75 —

News headlines (Yahoo Finance, 1h cache)

Milestone Pharmaceuticals (MIST) Stock Sees Fair Value Cut As Cardamyst Launch Concerns Persist
2026-11-17 13:10 · Yahoo
Milestone Pharmaceuticals Inc. Q3 2026 Earnings Call Summary
2026-11-13 22:02 · Yahoo
Milestone Pharmaceuticals Q3 Earnings Call Highlights
2026-11-13 16:14 · Yahoo
Why Is Milestone Pharmaceuticals Stock Rising 6% Following Its Third-Quarter Results?
2026-11-13 13:33 · Yahoo
Milestone Pharmaceuticals Reports Third Quarter 2026 Financial Results and Announces Cost-Efficiency Measures Designed to Extend Cash Runway Through AFib-RVR Phase 3 Data
2026-11-13 12:08 · Yahoo
Milestone Pharmaceuticals (MIST) Reports Q3 Loss, Beats Revenue Estimates
2026-11-13 12:00 · Yahoo
Milestone Pharmaceuticals: Q3 Earnings Snapshot
2026-11-13 11:55 · Yahoo
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-04 01:45 · Yahoo
Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026
2026-11-03 13:00 · Yahoo
New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation
2026-11-02 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.